Targeted polar or charged drug delivery, using opposite electrostatic charge

Targeted drug delivery using polar or charged drugs by opposite electrostatic charge, in breast cancer clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190904044697N6

Enrollment

Registered

2020-09-14

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Malignant cancer with solid tumor. Condition 2: Drug delivery. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: Patients with breast cancer with assessable solid mass are nominated according to the inclusion criteria, are treated with chemotherapy drugs and opposite electrost

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All breast cancer type patients, with different stages, by distinguished tissue biopsy to normal one which confirmed the tumor existence. Pathological or radiological evidence of tumor existence. All breast cancer patients become a chemotherapy candidate in neoadjuvant, adjutant? and post-operative circumstance. Patients who are indicated for administration polar water-soluble or charged chemotherapy drugs such as cisplatin, carboplatib, cyclophosphamide, doxorubicin

Exclusion criteria

Exclusion criteria: Patients who do not have appropriate general condition and need intensive care. Patients who have no assessable tumor for treatment evaluation. Coagulation disorders (INR>1.5) Thrombocytopenia (Platelets<150000) Anemia (Hemoglobin<12) Acute Infection Patients with pacemaker or any types of cardiac arrhythmia Abnormal biochemistry or electrolyte of the serum. Pregnancy Neutropenia (neutrophil<1500) Patients who are not receiving polar or charged chemotherapy drugs

Design outcomes

Primary

Measure	Time frame
Accurate tumor size under patch area. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: Imaging modalities such as sonography, mamography, MRI, etc.;Serum tumor marker. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: laboratory test on blood samples.;Clinical Manifestations. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: Accurate history taking and physical examination.;Pathological and microscopical features of the tumor. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: Biopsy taking and specific and non-specific staining of the tissue.;Immunohistochemical staining. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: Biopsy taking and specific staining of the tissue.	—

Measure

Time frame

Accurate tumor size under patch area. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: Imaging modalities such as sonography, mamography, MRI, etc.;Serum tumor marker. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: laboratory test on blood samples.;Clinical Manifestations. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: Accurate history taking and physical examination.;Pathological and microscopical features of the tumor. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: Biopsy taking and specific and non-specific staining of the tissue.;Immunohistochemical staining. Timepoint: 10 days after the first, second, third, and fourth courses of chemotherapy. Method of measurement: Biopsy taking and specific staining of the tissue.

—

Secondary

Measure	Time frame
Quality Of Life. Timepoint: 90 days. Method of measurement: Questionnaire about quality of life indicators based on EORTC QLQ-C30.;Evaluating long side effects of chemotherapy drugs. Timepoint: 90 days. Method of measurement: history taking and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTehran University of Medical Sciences

Tehran University of Medical Sciences

m.abdolahad@ut.ac.ir+98 21 8802 8367

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026